A calculating people: The spead of numeracy in early America By Patricia Cline Cohen. Chicago (University of Chicago Press). 1983. x + 271 pp. $22.50

Unknow

Volunteer Growth in America: A Review of Trends Since 1974

The Corporation has produced a national report that for the first time tracks volunteering over a 30-year period. "Volunteer Growth in America: A Review of Trends Since 1974" illustrates how volunteering has rebounded to a 30-year high today -- rising by more than 32 percent over the past 16 years -- after declining between 1974 and 1989. The report found that older teenagers (ages 16-19) have more than doubled their time spent volunteering since 1989; that far from being a "Me Generation," that Baby Boomers are volunteering at sharply higher rates than did the previous generation at mid-life; and that the volunteer rate for Americans ages 65 years and over has increased 64 percent since 1974; and the proportion of Americans volunteering with an educational or youth service organization has seen a 63 percent increase just since just 1989. "Volunteer Growth in America" is based on statistics from the U.S. Census Bureau and the Bureau of Labor Statistics. The findings are encouraging while demonstrating that more engagement is needed to achieve a national goal of raising the number of volunteers from 65 million in 2005 to 75 million by 2010

Sulfadoxine-pyrimethamine plus chloroquine or amodiaquine for uncomplicated falciparum malaria: a randomized, multisite trial to guide national policy in Uganda.

The use of combinations of inexpensive drugs for the treatment of malaria in Africa has been proposed as an interim policy while awaiting the widespread availability of more effective regimens. We compared sulfadoxine-pyrimethamine plus chloroquine or amodiaquine in three districts in Uganda. Patients aged 6 months or greater with uncomplicated falciparum malaria were enrolled and randomized to therapy. Safety, tolerability, and efficacy outcomes, adjusted by genotyping, were assessed over 28 days. Of 1,105 patients enrolled, 1,057 (96%) completed follow-up. For children less than 5 years old, the risk of clinical treatment failure adjusted by genotyping at the three sites ranged from 34% to 67% with chloroquine plus sulfadoxine-pyrimethamine and from 13% to 35% with amodiaquine plus sulfadoxine-pyrimethamine (risk differences 21-32%, P < 0.0001 at all sites). Serious adverse events were uncommon with both regimens. The risk of treatment failure with chloroquine plus sulfadoxine-pyrimethamine, the current standard in Uganda, was unacceptably high. Amodiaquine plus sulfadoxine-pyrimethamine was significantly more efficacious; however, existing levels of resistance raises concern about the useful therapeutic life-span of this regimen

Artemisinin versus Nonartemisinin Combination Therapy for Uncomplicated Malaria: Randomized Clinical Trials from Four Sites in Uganda

BACKGROUND: Drug resistance in Plasmodium falciparum poses a major threat to malaria control. Combination antimalarial therapy including artemisinins has been advocated recently to improve efficacy and limit the spread of resistance, but artemisinins are expensive and relatively untested in highly endemic areas. We compared artemisinin-based and other combination therapies in four districts in Uganda with varying transmission intensity. METHODS AND FINDINGS: We enrolled 2,160 patients aged 6 mo or greater with uncomplicated falciparum malaria. Patients were randomized to receive chloroquine (CQ) + sulfadoxine-pyrimethamine (SP); amodiaquine (AQ) + SP; or AQ + artesunate (AS). Primary endpoints were the 28-d risks of parasitological failure either unadjusted or adjusted by genotyping to distinguish recrudescence from new infections. A total of 2,081 patients completed follow-up, of which 1,749 (84%) were under the age of 5 y. The risk of recrudescence after treatment with CQ + SP was high, ranging from 22% to 46% at the four sites. This risk was significantly lower (p < 0.01) after AQ + SP or AQ + AS (7%–18% and 4%–12%, respectively). Compared to AQ + SP, AQ + AS was associated with a lower risk of recrudescence but a higher risk of new infection. The overall risk of repeat therapy due to any recurrent infection (recrudescence or new infection) was similar at two sites and significantly higher for AQ + AS at the two highest transmission sites (risk differences = 15% and 16%, p< 0.003). CONCLUSION: AQ + AS was the most efficacious regimen for preventing recrudescence, but this benefit was outweighed by an increased risk of new infection. Considering all recurrent infections, the efficacy of AQ + SP was at least as efficacious at all sites and superior to AQ + AS at the highest transmission sites. The high endemicity of malaria in Africa may impact on the efficacy of artemisinin-based combination therapy. The registration number for this trial is ISRCTN67520427 (http://www.controlled-trials.com/isrctn/trial/|/0/67520427.html)

THE SCIENTIFIC MIXED WITH THE POLITICAL: JOHN QUINCY, BROOKS, AND HENRY ADAMS

Abstract not availabl

THE SCIENTIFIC MIXED WITH THE POLITICAL: JOHN QUINCY, BROOKS, AND HENRY ADAMS

Abstract not availabl

Science in America a documentary history 1900 - 1939

xii, 490 p.; 23 cm